EGFR and non-small cell lung carcinoma: Irreversible EGFR-TKIs, such as BIBW2992, that can overcome the T790M-mediated resistance to gefitinib have been developed (12), however, clinical trials have failed to show that monotherapy with such irreversible EGFR-TKIs leads to any benefit in those patients with NSCLC refractory to gefitinib (13).